Chapman Partnership Names Symeria T. Hudson As Its New President and CEO

MIAMI (Dec. 4, 2018) – Chapman Partnership today announced the appointment of its new president and chief executive officer (CEO), Symeria T. Hudson, MBA. She will assume her new role on Jan. 2, 2019, succeeding H. Daniel Vincent, after a yearlong search by a special ad hoc search committee comprised of members from the organization’s board of trustees.

Hudson is a seasoned corporate executive with international experience in leading large-scale franchises, product portfolios, and driving product innovations for top medical technology/health care companies across the U.S. and Europe.

As president and CEO of Chapman Partnership, Hudson will report directly to the board of trustees. Her responsibilities will include overseeing the strategic, programmatic, financial, and managerial operations of the organization, in support of its mission and vision. Her role also entails closely collaborating with the board of trustees to develop the organization’s fundraising and revenue generation strategy and goals; securing and allocating sufficient resources to sustain the mission and operational requirements; and creating and implementing innovative marketing and brand initiatives to raise awareness of Chapman Partnership’s work in the community, among other duties.

“It is truly a privilege to serve as the president and CEO of Chapman Partnership and carry on the incredible mission, vision, and legacy of Alvah H. Chapman,” said Hudson, president and CEO of Chapman Partnership. “I am excited to work with a great leadership team with whom together, we will drive more innovative solutions to serve our residents, community partners, and existing and new stakeholders.”

Prior to Chapman Partnership, Hudson was based in West London, U.K., as the president of Global Franchises and Innovation for ConvaTec, PLC, a $1.8 billion, international medical products and technologies company with a focus on chronic care conditions. At ConvaTec, she was responsible for global marketing including strategy, commercial excellence, portfolio management, and research and development across three of the four chronic care franchises. She also served on the executive committee that drove ConvaTec’s flotation on the London Stock Market in 2016, the largest IPO by a health care company in Europe.

Prior to joining ConvaTec, Hudson served as the global franchise head for Renal Home Therapies, a $2.1 billion business operation for Baxter Corporation, focusing on strategy and new product innovation for patients with end stage renal disease. Before her tenure at Baxter, she served in several leadership roles throughout her career, including at Hospira, Inc. where she led product innovation, the execution of “go-to market” strategies, and sales force execution plans, which resulted in significant growth across the Medication Management Business Unit.

In 2015, she was named a “Top 50 Business Leader of Color” by Chicago United Organization. She also served as board member of the Kohl Children’s Museum and the Baxter Foundation, respectively in Chicago, IL. Hudson received her MBA from Harvard Business School and a bachelor’s of science from Alabama A&M University School of Business.


More news from Chapman Partnership: